Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

'Mad Money' host Jim Cramer weighs in on stock including: Viking Therapeutics, First Solar, RadNet, and Waste Management.

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Trading Advice for Viking Therapeutics Inc. VKTX including day trading swing trading and long term investing plans for VKTX ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...